Search results
Results from the WOW.Com Content Network
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
The most effective malaria vaccine is the R21/Matrix-M, with a 77% efficacy rate shown in initial trials and significantly higher antibody levels than with the RTS,S vaccine. It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy, [6] [7] and only the second malaria vaccine ...
This vaccine is the first to meet the World Health Organization's Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy. [144] Germany-based BioNTECH SE is developing an mRNA-based malaria vaccine BN165 [145] which has recently initiated a Phase 1 study [clinicaltrials.gov identifier: NCT05581641] in December 2022. The ...
Dengue is spread by several species of female mosquitoes of the Aedes genus, principally Aedes aegypti. [1] Infection can be prevented by mosquito elimination and the prevention of bites. [12] Two types of dengue vaccine have been approved and are commercially available.
Over the last twenty years, there has been a geographic spread of the disease. Dengue incidence rates have risen sharply within urban areas which have recently become endemic hot spots for the disease. [53] The recent spread of Dengue can also be attributed to rapid population growth, increased coagulation in urban areas, and global travel.
Chemoprophylaxis is also important in the transmission of malaria infection and resistance in defined populations (for example travelers). A hope for future of anti-malarial therapy is the development of an effective malaria vaccine. This could have enormous public health benefits, providing a cost-effective and easily applicable approach to ...
President Benigno Aquino III at the launching of the dengue vaccine school-based immunization program. In April 2016, the DOH launched the dengue vaccination campaign in Central Luzon, Calabarzon and Metro Manila, where about 700,000 individuals received at least one dose of the vaccine. [11] The government paid P3.5-billion for the vaccine. [10]
Dengue virus (DENV) is the cause of dengue fever.It is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus. [1] [2] Four serotypes of the virus have been found, and a reported fifth has yet to be confirmed, [3] [4] [5] all of which can cause the full spectrum of disease. [1]